ES2298425T7 - Derivados de fenil-piperazina como inhibidores de la captación de serotonina - Google Patents

Derivados de fenil-piperazina como inhibidores de la captación de serotonina Download PDF

Info

Publication number
ES2298425T7
ES2298425T7 ES02800051T ES02800051T ES2298425T7 ES 2298425 T7 ES2298425 T7 ES 2298425T7 ES 02800051 T ES02800051 T ES 02800051T ES 02800051 T ES02800051 T ES 02800051T ES 2298425 T7 ES2298425 T7 ES 2298425T7
Authority
ES
Spain
Prior art keywords
alk
phenyl
compounds
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES02800051T
Other languages
English (en)
Spanish (es)
Other versions
ES2298425T3 (es
Inventor
Thomas Ruhland
Garrick Smith
Benny Bang-Andersen
Ask Püschl
Ejner Moltzen
Kim Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2298425(T7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of ES2298425T3 publication Critical patent/ES2298425T3/es
Application granted granted Critical
Publication of ES2298425T7 publication Critical patent/ES2298425T7/es
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES02800051T 2001-10-04 2002-10-02 Derivados de fenil-piperazina como inhibidores de la captación de serotonina Active ES2298425T7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200101466 2001-10-04
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (2)

Publication Number Publication Date
ES2298425T3 ES2298425T3 (es) 2008-05-16
ES2298425T7 true ES2298425T7 (es) 2022-06-27

Family

ID=8160750

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02800051T Active ES2298425T7 (es) 2001-10-04 2002-10-02 Derivados de fenil-piperazina como inhibidores de la captación de serotonina
ES06016609T Expired - Lifetime ES2328725T3 (es) 2001-10-04 2002-10-02 Derivados de fenilpiridina como inhibidores de la reabsorcion de serotonina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06016609T Expired - Lifetime ES2328725T3 (es) 2001-10-04 2002-10-02 Derivados de fenilpiridina como inhibidores de la reabsorcion de serotonina.

Country Status (38)

Country Link
US (10) US7144884B2 (enExample)
EP (2) EP1749818B1 (enExample)
JP (3) JP3896116B2 (enExample)
KR (3) KR100783346B1 (enExample)
CN (1) CN1319958C (enExample)
AR (2) AR036659A1 (enExample)
AT (2) ATE441631T1 (enExample)
AU (2) AU2002333220C1 (enExample)
BE (1) BE2014C036I2 (enExample)
BR (3) BR122012009534C8 (enExample)
CA (1) CA2462110C (enExample)
CO (1) CO5580746A2 (enExample)
CY (3) CY1107924T1 (enExample)
DE (2) DE60225162T3 (enExample)
DK (2) DK1749818T3 (enExample)
EA (2) EA011096B1 (enExample)
EG (1) EG25095A (enExample)
ES (2) ES2298425T7 (enExample)
FR (1) FR14C0033I2 (enExample)
HR (1) HRP20040220A2 (enExample)
HU (3) HU228956B1 (enExample)
IL (1) IL160655A0 (enExample)
IS (2) IS2578B (enExample)
LT (1) LTC1436271I2 (enExample)
LU (1) LU92397I2 (enExample)
ME (1) ME00039B (enExample)
MX (1) MXPA04002959A (enExample)
MY (1) MY140950A (enExample)
NL (1) NL300652I2 (enExample)
NO (3) NO326443B1 (enExample)
NZ (1) NZ531556A (enExample)
PL (2) PL209253B1 (enExample)
PT (2) PT1436271E (enExample)
RS (2) RS52326B (enExample)
SI (1) SI1436271T1 (enExample)
UA (2) UA81749C2 (enExample)
WO (1) WO2003029232A1 (enExample)
ZA (1) ZA200401583B (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
AR043966A1 (es) * 2003-04-04 2005-08-17 Lundbeck & Co As H Derivados de 4- ( 2-feniloxifenil) - piperidina o 1,2,3,6 -tetrahidropiridina como inhibidores de la recaptacion de la serotonina
DE602004013314T2 (de) * 2003-04-04 2008-08-07 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6-tetrahydropyridin-derivate als serotonin-wiederaufnahme-hemmer
ZA200507181B (en) * 2003-04-04 2007-03-28 Lundbeck & Co As 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
CA2521258C (en) * 2003-04-04 2009-12-01 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
AU2004303461B2 (en) 2003-12-23 2011-04-28 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
ATE435216T1 (de) * 2005-02-10 2009-07-15 Neurosearch As Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
SI2044020T1 (sl) * 2006-06-16 2011-06-30 Lundbeck & Co As H Kristaliniäśne oblike 4-(2-(4-metilfenilsulfanil)-fenil)piperidina s kombiniranim zaviranjem ponovnega privzema serotonina in norepinefrina za zdravljenje nevropatske boleäśine
BR122020011920A2 (pt) * 2006-06-16 2020-08-25 Lundbeck & Co As H composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
ES2361949T3 (es) * 2006-06-16 2011-06-24 H. Lundbeck A/S Formas cristalinas de 4-[2-(4-metilfenilsulfanil)-fenil]piperidina con inhibición de la reabsorción de serotonina y norepinefrina combinada para el tratamiento del dolor neuropático.
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
HRP20140044T1 (hr) 2007-06-15 2014-02-14 H. Lundbeck A/S 4-[2-(4-metilfenilsulfanil)fenil]piperidin za lijeäśenje iritabilnog sindroma crijeva (ibs)
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
WO2010056938A1 (en) 2008-11-14 2010-05-20 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
GEP20135938B (en) * 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine
MX2012002199A (es) * 2009-08-24 2012-03-16 Lundbeck & Co As H Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina.
WO2011053706A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CN103096879B (zh) 2010-04-30 2014-12-10 武田药品工业株式会社 肠溶片剂
WO2011136376A1 (ja) * 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR101879474B1 (ko) 2011-06-20 2018-07-17 하. 룬드벡 아크티에셀스카브 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단
WO2013074676A2 (en) 2011-11-14 2013-05-23 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
LT2800746T (lt) * 2012-01-03 2019-06-10 H. Lundbeck A/S 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazino gavimo būdas
CN104797566B (zh) 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
CN104995181B (zh) * 2013-02-22 2017-03-08 H.隆德贝克有限公司 沃替西汀生产方法
EP2981520B1 (en) 2013-04-04 2019-03-06 LEK Pharmaceuticals d.d. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
WO2015044963A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN108348486A (zh) * 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
EP3337789A1 (en) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Process for preparation of vortioxetine hydrobromide
EP3362058B1 (en) * 2015-10-14 2021-09-01 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20190290641A1 (en) * 2016-07-15 2019-09-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
KR20190032418A (ko) * 2016-07-22 2019-03-27 지앙수 인화뤄캉 파마슈티컬 리서치 앤드 디벨롭먼트 컴퍼니 리미티드 보티옥세틴 유사체와 용도 및 이의 제조
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
US11020390B2 (en) 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
EP3585388A4 (en) 2017-02-23 2020-08-12 Unichem Laboratories Ltd IMPROVED PROCESS FOR PREPARATION AND PURIFICATION OF VORTIOXETINE BROMHYDRATE
KR102551433B1 (ko) 2017-04-25 2023-07-04 하. 룬드벡 아크티에셀스카브 보르티옥세틴 hbr 알파-형태의 제조 방법
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
PT3810582T (pt) 2018-06-20 2024-04-09 Vio Ag Pharmaceuticals S A Uma abordagem de ativação de c-h organo-pseudocatalítica em um só recipiente para a preparação de vortioxetina e intermediário de vortioxetina
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
AU2021246973A1 (en) 2020-04-03 2022-11-03 H. Lundbeck A/S 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151751B1 (enExample) 1971-04-13 1973-11-19
CS151755B1 (enExample) 1971-04-13 1973-11-19
CS151752B1 (enExample) 1971-04-13 1973-11-19
CS151753B1 (enExample) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
ATE294778T1 (de) 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2681877A1 (en) * 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
EA200101017A1 (ru) 1999-04-02 2002-04-25 Айкос Корпорейшен Ингибиторы связывания lfa-1 с icam и их использование
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
IL148677A0 (en) * 1999-09-14 2002-09-12 Pharmacopeia Inc Article comprising a multi-channel dispensing head
MXPA02006223A (es) * 1999-12-30 2002-12-05 Lundbeck & Co As H Derivados de fenilpiperazina sustituida, su preparcion y uso.
WO2001049681A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
CA2431996A1 (en) * 2001-01-23 2002-08-01 Vincent Mancuso Melanocortin receptor agonists
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60219521T2 (de) * 2001-12-20 2007-08-16 H. Lundbeck A/S Aryloxyphenyl und arylsulfanylphenylderivate
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CA2521258C (en) * 2003-04-04 2009-12-01 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
BR122020011920A2 (pt) * 2006-06-16 2020-08-25 Lundbeck & Co As H composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto

Also Published As

Publication number Publication date
ES2328725T3 (es) 2009-11-17
PL210551B1 (pl) 2012-02-29
AU2002333220C1 (en) 2023-10-05
DK1749818T3 (da) 2009-10-12
AU2006215994B2 (en) 2008-11-13
BR122012009534B8 (pt) 2019-01-29
HU230189B1 (hu) 2015-09-28
CN1319958C (zh) 2007-06-06
US20060084662A1 (en) 2006-04-20
ME00039B (me) 2010-06-10
ATE441631T1 (de) 2009-09-15
BR122012023120B8 (pt) 2022-01-18
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
US7683053B2 (en) 2010-03-23
US20140163043A1 (en) 2014-06-12
KR20040047886A (ko) 2004-06-05
NO2014011I2 (no) 2015-08-31
FR14C0033I1 (enExample) 2014-06-13
KR100770194B1 (ko) 2007-10-25
DK1436271T6 (da) 2022-06-27
CY2014022I2 (el) 2015-12-09
AU2006215994A9 (en) 2006-10-05
KR100842702B1 (ko) 2008-07-01
ES2298425T3 (es) 2008-05-16
LTC1436271I2 (lt) 2016-09-12
DE60225162D1 (de) 2008-04-03
AR036659A1 (es) 2004-09-22
CY1110064T1 (el) 2015-01-14
UA93857C2 (uk) 2011-03-25
NO332355B1 (no) 2012-09-03
US8476279B2 (en) 2013-07-02
US20070060574A1 (en) 2007-03-15
EP1749818A3 (en) 2008-04-02
ATE386730T1 (de) 2008-03-15
MY140950A (en) 2010-02-12
US7144884B2 (en) 2006-12-05
CA2462110A1 (en) 2003-04-10
NL300652I1 (enExample) 2016-01-18
AU2006215994A2 (en) 2006-10-05
CY2014022I1 (el) 2015-12-09
RS52865B (sr) 2013-12-31
US20160137620A1 (en) 2016-05-19
KR100783346B1 (ko) 2007-12-07
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
CO5580746A2 (es) 2005-11-30
CA2462110C (en) 2010-05-11
CN1561336A (zh) 2005-01-05
CA2462110E (en) 2003-04-10
PT1436271E (pt) 2008-04-10
UA81749C2 (uk) 2008-02-11
US20180127389A1 (en) 2018-05-10
IS2732B (is) 2011-04-15
BE2014C036I2 (enExample) 2021-11-22
RS20120158A3 (en) 2013-10-31
SI1436271T1 (sl) 2008-06-30
PL368442A1 (pl) 2005-03-21
MXPA04002959A (es) 2004-07-05
DK1436271T3 (da) 2008-06-09
BR0212733B1 (pt) 2014-05-13
EA200400498A1 (ru) 2004-08-26
JP2005505585A (ja) 2005-02-24
HUP0402313A3 (en) 2010-03-29
US7148238B2 (en) 2006-12-12
PL209253B1 (pl) 2011-08-31
US20110009423A1 (en) 2011-01-13
BR0212733A (pt) 2004-11-16
LTPA2014013I1 (lt) 2014-04-25
EP1749818B1 (en) 2009-09-02
JP3955614B2 (ja) 2007-08-08
AU2002333220A2 (en) 2003-04-14
US20210276966A1 (en) 2021-09-09
US20050014740A1 (en) 2005-01-20
RS20120158A2 (sr) 2012-10-31
MEP6508A (xx) 2010-02-10
US20120302553A1 (en) 2012-11-29
RS27704A (sr) 2006-10-27
HRP20040220A2 (en) 2005-02-28
US10844029B2 (en) 2020-11-24
CY1107924T1 (el) 2013-09-04
EP1436271B1 (en) 2008-02-20
BR122012009534B1 (pt) 2018-02-27
NO20083446L (no) 2004-04-21
EP1436271A1 (en) 2004-07-14
JP3896116B2 (ja) 2007-03-22
BRPI0212733B8 (pt) 2021-05-25
DE60233608D1 (de) 2009-10-15
EA007537B1 (ru) 2006-10-27
IS2578B (is) 2010-02-15
NO20041628L (no) 2004-04-21
WO2003029232A1 (en) 2003-04-10
PT1749818E (pt) 2009-10-06
EA200601269A1 (ru) 2007-02-27
KR20070103515A (ko) 2007-10-23
AU2002333220B2 (en) 2008-02-07
IL160655A0 (en) 2004-07-25
LU92397I2 (fr) 2014-05-12
NO326443B1 (no) 2008-12-08
AR066460A2 (es) 2009-08-19
HK1072600A1 (zh) 2005-09-02
IS7164A (is) 2004-02-26
FR14C0033I2 (fr) 2014-11-14
NO2014011I1 (no) 2014-05-13
ZA200401583B (en) 2005-05-25
JP3955613B2 (ja) 2007-08-08
JP2007051149A (ja) 2007-03-01
HU228956B1 (en) 2013-07-29
EP1436271B3 (en) 2022-04-20
US7138407B2 (en) 2006-11-21
AU2006215994A1 (en) 2006-10-05
KR20060118020A (ko) 2006-11-17
NL300652I2 (enExample) 2016-01-18
HUS1400012I1 (hu) 2020-12-28
EA007537B3 (ru) 2015-02-27
EG25095A (en) 2011-08-17
HUP0402313A2 (hu) 2005-02-28
EA011096B1 (ru) 2008-12-30
DE60225162T2 (de) 2009-02-12
EP1749818A2 (en) 2007-02-07
US8110567B2 (en) 2012-02-07
BR122012023120B1 (pt) 2017-03-21
US9708280B2 (en) 2017-07-18
JP2007031447A (ja) 2007-02-08
IS8806A (is) 2009-03-10
US20060089368A1 (en) 2006-04-27
US9090575B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
ES2298425T7 (es) Derivados de fenil-piperazina como inhibidores de la captación de serotonina
AU2002333220A1 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors